MedImmune

From WikiMD.org
Jump to navigation Jump to search

MedImmune

MedImmune (pronounced: Med-Im-mune) is a global biotechnology company, specializing in the research, development, and commercialization of vaccines and antibody therapies. It was founded in 1988 and is currently a subsidiary of AstraZeneca, a multinational pharmaceutical and biopharmaceutical company.

Etymology

The name "MedImmune" is a portmanteau of the words "Medical" and "Immune", reflecting the company's focus on developing treatments to enhance the body's immune response to various diseases.

History

MedImmune was established in 1988 in Gaithersburg, Maryland, USA. The company's initial focus was on vaccines and immune system therapies for infectious diseases and cancer. In 2007, MedImmune was acquired by AstraZeneca, one of the world's leading pharmaceutical companies. Since then, MedImmune has continued to operate as a subsidiary of AstraZeneca, contributing significantly to its parent company's pipeline of innovative medicines.

Products and Research

MedImmune's product portfolio includes Synagis, a monoclonal antibody for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients. The company is also known for its development of FluMist, a nasal spray influenza vaccine.

In addition to its marketed products, MedImmune has a robust pipeline of investigational medicines aimed at treating conditions such as asthma, cancer, autoimmune diseases, and cardiovascular diseases. The company's research efforts are grounded in its expertise in immunology, oncology, and virology.

Related Terms

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski